BioSpectrum the business of Bio & Health Sciences ASIA EDITION

LivaNova completes TandemLife acquisition

April 6, 2018 | News

Under the terms of the agreement, LivaNova paid $200 million to TandemLife at closing with an additional $50 million to be paid based on specified regulatory milestones.



Singapore – LivaNova, a market-leading medical technology company has completed its acquisition of privately held TandemLife, a privately held company focused on advanced cardiopulmonary temporary support solutions for $200M in cash plus up to an additional $50M in regulatory milestones.

“The acquisition of TandemLife allows us to complement our portfolio with a complete set of solutions for Extracorporeal Life Support and Percutaneous Mechanical Circulatory Support,” said Damien McDonald, LivaNova’s Chief Executive Officer. “Expanding our existing line of cardiopulmonary products will advance patient care options and improve quality of medical care.”

The acquisition is projected to be modestly accretive in 2018.